Modeling psychiatric disorders for developing effective treatments
Recent advances in identifying risk-associated genes have provided unprecedented opportunities for developing animal models for psychiatric disease research with the goal of attaining translational utility to ultimately develop novel treatments. However, at this early stage, successful translation h...
| Main Authors: | , |
|---|---|
| Other Authors: | |
| Format: | Article |
| Published: |
Nature Publishing Group
2017
|
| Online Access: | http://hdl.handle.net/1721.1/112264 https://orcid.org/0000-0002-8665-3912 https://orcid.org/0000-0002-8021-277X |
| _version_ | 1826193503801049088 |
|---|---|
| author | Kaiser, Tobias Feng, Guoping |
| author2 | Massachusetts Institute of Technology. Department of Brain and Cognitive Sciences |
| author_facet | Massachusetts Institute of Technology. Department of Brain and Cognitive Sciences Kaiser, Tobias Feng, Guoping |
| author_sort | Kaiser, Tobias |
| collection | MIT |
| description | Recent advances in identifying risk-associated genes have provided unprecedented opportunities for developing animal models for psychiatric disease research with the goal of attaining translational utility to ultimately develop novel treatments. However, at this early stage, successful translation has yet to be achieved. Here we review recent advances in modeling psychiatric disease, discuss the utility and limitations of animal models, and emphasize the importance of shifting from behavioral analysis to identifying neurophysiological abnormalities, which are likely to be more conserved across species and thus may increase translatability. Looking forward, we envision that preclinical research will align with clinical research to build a common framework of comparable neurobiological abnormalities and to help form subgroups of patients on the basis of similar pathophysiology. Experimental neuroscience can then use animal models to discover mechanisms underlying distinct abnormalities and develop strategies for effective treatments. |
| first_indexed | 2024-09-23T09:40:13Z |
| format | Article |
| id | mit-1721.1/112264 |
| institution | Massachusetts Institute of Technology |
| last_indexed | 2024-09-23T09:40:13Z |
| publishDate | 2017 |
| publisher | Nature Publishing Group |
| record_format | dspace |
| spelling | mit-1721.1/1122642022-09-26T13:00:30Z Modeling psychiatric disorders for developing effective treatments Kaiser, Tobias Feng, Guoping Massachusetts Institute of Technology. Department of Brain and Cognitive Sciences McGovern Institute for Brain Research at MIT Kaiser, Tobias Feng, Guoping Recent advances in identifying risk-associated genes have provided unprecedented opportunities for developing animal models for psychiatric disease research with the goal of attaining translational utility to ultimately develop novel treatments. However, at this early stage, successful translation has yet to be achieved. Here we review recent advances in modeling psychiatric disease, discuss the utility and limitations of animal models, and emphasize the importance of shifting from behavioral analysis to identifying neurophysiological abnormalities, which are likely to be more conserved across species and thus may increase translatability. Looking forward, we envision that preclinical research will align with clinical research to build a common framework of comparable neurobiological abnormalities and to help form subgroups of patients on the basis of similar pathophysiology. Experimental neuroscience can then use animal models to discover mechanisms underlying distinct abnormalities and develop strategies for effective treatments. National Institute of Mental Health (U.S.) (Grant 5R01MH097104) 2017-11-21T20:19:44Z 2017-11-21T20:19:44Z 2015-09 2015-05 2017-11-06T12:55:31Z Article http://purl.org/eprint/type/JournalArticle 1078-8956 1546-170X http://hdl.handle.net/1721.1/112264 Kaiser, Tobias, and Feng, Guoping. “Modeling Psychiatric Disorders for Developing Effective Treatments.” Nature Medicine 21, 9 (September 2015): 979–988 © 2015 Nature America, Inc https://orcid.org/0000-0002-8665-3912 https://orcid.org/0000-0002-8021-277X http://dx.doi.org/10.1038/NM.3935 Nature Medicine Creative Commons Attribution-Noncommercial-Share Alike http://creativecommons.org/licenses/by-nc-sa/4.0/ application/pdf Nature Publishing Group PMC |
| spellingShingle | Kaiser, Tobias Feng, Guoping Modeling psychiatric disorders for developing effective treatments |
| title | Modeling psychiatric disorders for developing effective treatments |
| title_full | Modeling psychiatric disorders for developing effective treatments |
| title_fullStr | Modeling psychiatric disorders for developing effective treatments |
| title_full_unstemmed | Modeling psychiatric disorders for developing effective treatments |
| title_short | Modeling psychiatric disorders for developing effective treatments |
| title_sort | modeling psychiatric disorders for developing effective treatments |
| url | http://hdl.handle.net/1721.1/112264 https://orcid.org/0000-0002-8665-3912 https://orcid.org/0000-0002-8021-277X |
| work_keys_str_mv | AT kaisertobias modelingpsychiatricdisordersfordevelopingeffectivetreatments AT fengguoping modelingpsychiatricdisordersfordevelopingeffectivetreatments |